KYTX — Kyverna Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1994702 ·
Last close
$6.82
Market Cap
$421.77M
52W High
$13.67
52W Low
$5.30
ADV30
876,705
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -39,556,000 | -38,319,000 | 219,823,000 | 31,806,000 | 54,274,000 |
| Mar 2026 | 0 | — | -41,367,000 | -39,728,000 | 257,024,000 | 32,194,000 | 61,444,000 |
| Dec 2025 | 0 | — | -39,282,000 | -37,804,000 | 293,826,000 | 124,093,000 | 61,550,000 |
| Sep 2025 | 0 | — | -38,727,000 | -36,787,000 | 187,156,000 | 34,164,000 | 35,210,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-150,394,000
Investing CF
$-15,764,000
Financing CF
$141,481,000
CapEx
$-1,461,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.28
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-464,555,000
Inventory
—
Receivables
—
ST Investments
$204,252,000
EBIT TTM
$-155,268,000
Pretax Income TTM
$-156,400,000
Interest Exp TTM
$1,132,000
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -169,827,000 | -161,307,000 | 293,826,000 | 61,550,000 | 232,276,000 | -153,712,000 |
| Dec 2024 | 0 | -142,604,000 | -127,477,000 | 304,645,000 | 38,058,000 | 266,587,000 | -114,250,000 |
| Dec 2023 | 0 | -62,406,000 | -60,366,000 | 75,195,000 | 206,592,000 | -131,397,000 | -52,410,000 |
| Dec 2022 | 7,025,000 | -29,384,000 | -28,893,000 | 66,924,000 | 140,921,000 | -73,997,000 | -36,113,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.07
Max Pain — expiry 2026-12-18
max pain strike: $7.50 · spot: $6.82 · call oi: 4,169 · put oi: 709
Expected Move to 2026-12-18:
±$3.38
(49.49%) —
implied range
$3.45 –
$10.20
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AGEN | AGENUS INC | $424.54M | $9.43 | — |
| EIKN | Eikon Therapeutics, Inc. | $428.45M | $7.91 | — |
| ZURA | Zura Bio Ltd | $392.90M | $4.10 | — |
| TECX | Tectonic Therapeutic, Inc. | $459.61M | $23.51 | — |
| EDIT | Editas Medicine, Inc. | $385.49M | $2.51 | — |
News headlines (Yahoo Finance, 1h cache)
KYTX Stock Reverses Gains After One-Year Cell Therapy Trial Data — But CEO Says Disease Burden Justifies A Premium Price
2026-09-24 18:28 · Yahoo
Kyverna stock jumps on positive one-year therapy data
2026-09-24 14:05 · Yahoo
Kyverna Reports One-Year Miv-Cel Data From SPS and gMG Trials
2026-09-24 10:39 · Yahoo
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
2026-09-24 10:00 · Yahoo
Kyverna Therapeutics to Present at Upcoming Investor Conferences
2026-09-02 20:05 · Yahoo
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
2026-09-02 12:32 · Yahoo
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
2026-08-11 20:02 · Yahoo
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
2026-07-27 12:00 · Yahoo
Kyverna Therapeutics Sinks 13%: Here’s Why
2026-07-10 19:59 · Yahoo
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
2026-06-22 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.